10%, a body mass index greater than or equal to 25 kg/m^2, and/or NASH Clinical Research Network (CRN) fibrosis stage 1-3.

15. The method of claim **14**, wherein said hepatic fat fraction is determined by magnetic resonance imaging and/or said NASH CRN fibrosis stage is determined by a liver biopsy.

16. The method of claim **12**, wherein said modified FGF-21 polypeptide is administered at a frequency of about once per week.

17. The method of claim **12**, wherein said modified FGF-21 polypeptide is administered at a frequency of about once per day, about twice per week, or about once per two weeks, about once per three weeks, or about once per four weeks.

18. The method of claim **12**, wherein said modified FGF-21 polypeptide is administered in a dosage of about 20 mg per week.

19. The method of claim **12**, wherein said modified FGF-21 polypeptide is administered in a dosage of about 40 mg per week.

20. A method of treating NASH in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising the polypeptide of SEQ ID NO:201, wherein the para-acetyl-phenylalanine residue thereof is linked to a poly(ethylene glycol) moiety having a molecular weight of about 30 kDa, wherein said modified FGF-21 polypeptide is administered by subcutaneous injection about once per week.

21. The method of claim **20**, wherein said modified FGF-21 polypeptide is administered in a dosage of about 20 mg per week.

22. The method of claim **20**, wherein said modified FGF-21 polypeptide is administered in a dosage of about 40 mg per week.

* * * * *